Basel, Switzerland

Eckhard Weber

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Eckhard Weber in Urinary Incontinence Treatment

Introduction

Eckhard Weber is a distinguished inventor based in Basel, Switzerland. He has significantly contributed to the field of pharmaceuticals, particularly in the treatment of urinary incontinence. With a strong foundation in research and innovation, Eckhard has made notable advancements through his patent work.

Latest Patents

Eckhard Weber holds a patent for the use of neurokinin antagonists in the treatment of urinary incontinence. This invention concerns compounds of a specific formula, where various components are defined in detail within the patent specification. The primary focus of this invention is their application as pharmaceuticals, aimed at effectively treating urinary incontinence, thus providing a valuable solution for individuals affected by this condition.

Career Highlights

Currently, Eckhard Weber is associated with Novartis AG, where he continues to advance his research and development efforts in the pharmaceutical sector. His work not only exemplifies his dedication to innovation but also reflects the importance of addressing critical health issues through scientific advancements.

Collaborations

Throughout his career, Eckhard has collaborated with other professionals in the field, including notable coworkers such as Paul William Glue and Kevin Hall McAllister. These partnerships emphasize the collaborative nature of innovation in the pharmaceutical industry, where shared expertise leads to significant breakthroughs.

Conclusion

Eckhard Weber's innovative work in the treatment of urinary incontinence represents a pivotal development in pharmaceutical research. His patent on neurokinin antagonists highlights the vital role that inventors play in improving healthcare. As he continues his work at Novartis AG, the potential for future innovations remains promising, benefiting countless individuals in need.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…